DiNardo, Courtney D.

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Arber, D. A., Orazi, A., Hasserjian, R. P., Borowitz, M. J., Calvo, K. R., Kvasnicka, H.-M., Wang, S. A., Bagg, A., Barbui, T., Branford, S., et al. (2022) · Blood

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 2,945

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

DiNardo, C. D., Jonas, B. A., Pullarkat, V., Thirman, M. J., Garcia, J. S., Wei, A. H., Konopleva, M., Döhner, H., Letai, A., Fenaux, P., et al. (2020) · New England Journal of Medicine

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 2,900

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

DiNardo, C. D., Pratz, K., Pullarkat, V., Jonas, B. A., Arellano, M., Becker, P. S., Frankfurt, O., Konopleva, M., Wei, A. H., Kantarjian, H. M., et al. (2019) · Blood

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 1,825

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Stein, E. M., DiNardo, C. D., Pollyea, D. A., Fathi, A. T., Roboz, G. J., Altman, J. K., Stone, R. M., DeAngelo, D. J., Levine, R. L., Flinn, I. W., et al. (2017) · Blood

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 1,516

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

Yang, H., Bueso-Ramos, C., DiNardo, C., Estecio, M. R., Davanlou, M., Geng, Q.-R., Fang, Z., Nguyen, M., Pierce, S., Wei, Y., et al. (2014) · Leukemia

Cancer Immunotherapy and BiomarkersAcute Myeloid Leukemia Research

Cited by 688

Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study

Takahashi, K., Wang, F., Kantarjian, H., Doss, D., Khanna, K., Thompson, E., Zhao, L., Patel, K., Neelapu, S., Gumbs, C., et al. (2017) · The Lancet Oncology

Acute Myeloid Leukemia ResearchMultiple and Secondary Primary Cancers

Cited by 399

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML

DiNardo, C. D., Ravandi, F., Agresta, S., Konopleva, M., Takahashi, K., Kadia, T., Routbort, M., Patel, K. P., Brandt, M., Pierce, S., et al. (2015) · American Journal of Hematology

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 325

Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes

Matre, P., Velez, J., Jacamo, R., Qi, Y., Su, X., Cai, T., Chan, S. M., Lodi, A., Sweeney, S. R., Ma, H., et al. (2016) · Oncotarget

Acute Myeloid Leukemia ResearchCancer, Hypoxia, and Metabolism

Cited by 185

Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax

Kim, K., Maiti, A., Loghavi, S., Pourebrahim, R., Kadia, T. M., Rausch, C. R., Furudate, K., Daver, N. G., Alvarado, Y., Ohanian, M., et al. (2021) · Cancer

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 161

New directions for emerging therapies in acute myeloid leukemia: the next chapter

Daver, N., Wei, A. H., Pollyea, D. A., Fathi, A. T., Vyas, P., & DiNardo, C. D. (2020) · Blood Cancer Journal

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 159

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine

Pollyea, D. A., Pratz, K. W., Wei, A. H., Pullarkat, V., Jonas, B. A., Recher, C., Babu, S., Schuh, A. C., Dail, M., Sun, Y., et al. (2022) · Clinical Cancer Research

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 159

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial

Short, N. J., Kantarjian, H. M., Loghavi, S., Huang, X., Qiao, W., Borthakur, G., Kadia, T. M., Daver, N., Ohanian, M., Dinardo, C. D., et al. (2019) · The Lancet Haematology

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 120

Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis

Boddu, P., Kantarjian, H. M., Garcia-Manero, G., Ravandi, F., Verstovsek, S., Jabbour, E., Borthakur, G., Konopleva, M., Bhalla, K. N., Daver, N., et al. (2017) · Blood Advances

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 112

The outcomes of patients with chronic myeloid leukemia treated with third‐line BCR::ABL1 tyrosine kinase inhibitors

Jabbour, E. J., Sasaki, K., Haddad, F. G., Issa, G. C., Garcia‐Manero, G., Kadia, T. M., Jain, N., Yilmaz, M., DiNardo, C. D., Patel, K. P., et al. (2023) · American Journal of Hematology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 22